| 发布于: | 雪球 | 回复：8 | 喜欢：0 |
我以前分析过恒瑞的PD1. 基本上来看至少没有比已经上市的3家更好，所以incy才会放弃。但这并不代表在国内无法上市。 阿帕替尼和艾克替尼都不是最好的同类药品但是在国内也算是先进生产力。。。卖的有声有色
Updated data from a Phase 1 clinical trial assessing BeiGene's (BGNE+2.6%) PD-1 inhibitor BGB-A317 in patients with advanced solid tumors showed greater than a 38% disease control rate. The results were presented at the Society for Immunotherapy of Cancer 31st Annual Meeting in National Harbor, MD.
In 99 evaluable patients as of September 30, 15 (15%) were partial responders and 23 (23%) had stable disease implying a disease control rate of 38%. 87% (n=13/15) of the partial responders remain on treatment with duration of response ranging from 28 - 47 weeks. Responders include renal cell carcinoma, urothelial carcinoma, gastric cancer, Merkel cell carcinoma, naospharyngeal cancer and penis squamous cell carcinoma an duodenal carcinoma.
The most common treatment-related adverse events (TRAEs) were fatigue (19%), diarrhea (13%), rash (11%), pruritis (11%), nausea (8%), hypothyroidism (7%) and infusion-related reactions (6%).
The study will advance to a 1b phase during which flat dosing of 200 mg and 300 mg every three weeks will be explored.
详细的细分数据在conference里面我看了。一时间找不到。。